Advertisement

Tumor Biology

, Volume 35, Issue 8, pp 7407–7413 | Cite as

Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis

  • Zhenyin Liu
  • Fei Gao
  • Guang Yang
  • Sristi Singh
  • Mingjian Lu
  • Tao Zhang
  • Zhihui Zhong
  • Fujun Zhang
  • Rijie Tang
Research Article

Abstract

The aim of this meta-analysis was to compare the effectiveness of combination of radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) with that of RFA alone in patients with hepatocellular carcinoma (HCC). Randomized controlled trials comparing RFA plus TACE with RFA alone for HCC were included into this meta-analysis, and the search strategy followed the requirement of the Cochrane Library Handbook. Overall survival rate and recurrence-free survival rate were analyzed and compared by using Review Manager (version 5). We identified 7 randomized controlled trials comprising 571 patients who were treated by RFA plus TACE versus RFA alone for HCC. Meta-analyses showed that the combination of RFA and TACE was associated with a significantly higher overall survival rates (OR1 year = 2.39, 95 % CI, 1.35–4.21, P = 0.003; OR3 years = 1.85, 95 %CI 1.26–2.71, P = 0.002), and recurrence-free survival rate (OR1 year = 2.00, 95 % CI 1.26–3.18, P = 0.003; OR3 years = 2.13, 95 %CI 1.41–3.20, P < 0.001). Additionally, the quality of the evidence was high for the 1- and 3-year survival rate; no evidence of publication bias was observed. The combination of RFA with TACE can improve the overall survival rate and the recurrence-free survival rate for patients with HCC.

Keywords

Radiofrequency ablation Transarterial chemoembolization Hepatocellular carcinoma Survival rate Meta-analysis 

Notes

Acknowledgments

This work was supported by the Natural Science Foundation of China (Grant No. 81371654) and the Major Project of Science and Technology of Guangzhou (Grant number 132400027).

Conflicts of interest

None.

References

  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRefGoogle Scholar
  2. 2.
    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–17.PubMedCrossRefGoogle Scholar
  3. 3.
    Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519–24.PubMedCrossRefGoogle Scholar
  4. 4.
    Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–42.PubMedCrossRefGoogle Scholar
  5. 5.
    N'Kontchou G, Mahamoudi A, Aout M, Ganne-Carrie N, Grando V, Coderc E, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 western patients with cirrhosis. Hepatology. 2009;50:1475–83.PubMedCrossRefGoogle Scholar
  6. 6.
    Rossi S, Ravetta V, Rosa L, Ghittoni G, Viera FT, Garbagnati F, et al. Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: a long-term cohort study. Hepatology. 2011;53:136–47.PubMedCrossRefGoogle Scholar
  7. 7.
    Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2008;47:82–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131:461–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Kim JW, Kim JH, Won HJ, Shin YM, Yoon HK, Sung KB, et al. Hepatocellular carcinomas 2–3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation vs. Radiofrequency ablation alone. Eur J Radiol. 2012;81:e189–93.PubMedCrossRefGoogle Scholar
  10. 10.
    Kim JH, Won HJ, Shin YM, Kim SH, Yoon HK, Sung KB, et al. Medium-sized (3.1–5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Ann Surg Oncol. 2011;18:1624–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Tiong L, Maddern GJ. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg. 2011;98:1210–24.PubMedCrossRefGoogle Scholar
  12. 12.
    Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2013;139:653–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Wang W, Shi J, Xie WF. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int. 2010;30:741–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol. 2013;19:3872–82.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Cheng BQ, Jia CQ, Liu CT, Fan W, Wang QL, Zhang ZL, et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA. 2008;299:1669–77.PubMedCrossRefGoogle Scholar
  16. 16.
    Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  18. 18.
    MANTEL N, HAENSZEL W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  19. 19.
    Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013;31:426–32.PubMedCrossRefGoogle Scholar
  20. 20.
    Aikata H, Shirakawa H, Takaki S. Radiofrequency ablation combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. Hepatology 2006;44:A487nt 2013;33:375-383.Google Scholar
  21. 21.
    Kang CB, Xu HB, Wang SL, Rui B. Treatment of large hepatoma by TACE in combination with RFA. Zhonghua Gandan Waike Zazhi. 2007;13:828–30.Google Scholar
  22. 22.
    Peng ZW, Zhang YJ, Liang HH, Lin XJ, Guo RP, Chen MS. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus rf ablation alone: a prospective randomized trial. Radiology. 2012;262:689–700.PubMedCrossRefGoogle Scholar
  23. 23.
    Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer. 2010;116:5452–60.PubMedCrossRefGoogle Scholar
  24. 24.
    Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology. 2009;252:905–13.PubMedCrossRefGoogle Scholar
  25. 25.
    Yang P, Liang M, Zhang Y, Shen B. Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC. Adv Ther. 2008;25:787–94.PubMedCrossRefGoogle Scholar
  26. 26.
    Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgro G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol. 2010;52:380–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7:448–58.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2009;49:453–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Kong QF, Jiao JB, Chen QQ, Li L, Wang DG, Lv B. Comparative effectiveness of radiofrequency ablation with or without transarterial chemoembolization for hepatocellular carcinoma. Tumour Biol. 2014;35:2655–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Jiang G, Xu X, Ren S, Wang L. Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma. Tumour Biol. 2014;35:3405–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Shi M, Zhang CQ, Zhang YQ, Liang XM, Li JQ. Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin. World J Surg. 2004;28:376–81.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Zhenyin Liu
    • 1
  • Fei Gao
    • 1
  • Guang Yang
    • 1
  • Sristi Singh
    • 1
  • Mingjian Lu
    • 1
  • Tao Zhang
    • 1
  • Zhihui Zhong
    • 1
  • Fujun Zhang
    • 1
  • Rijie Tang
    • 2
  1. 1.Department of Imaging and Interventional Radiology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer MedicineSun Yat-sen University Cancer CenterGuangzhouPeople’s Republic of China
  2. 2.Department of Medical Imaging and Interventional RadiologyCancer Center of Guangzhou Medical UniversityGuangzhouPeople’s Republic of China

Personalised recommendations